

<del>National Imaging Associates, Inc.</del>	
<del>Clinical guidelines PELVIS MRI</del>	<del>Original Date: September 1997</del>
<del>CPT Codes: 72195, 72196, 72197</del>	<del>Last Revised Date: April 2021</del>
<del>Guideline Number: NIA_CG_037</del>	<del>Implementation Date: January 2022</del>

## AmeriHealth Caritas Louisiana

<u>National Imaging Associates, Inc.*</u>	
<u>Clinical guidelines PELVIS MRI</u>	<u>Original Date: September 1997</u>
<u>CPT Codes: 72195, 72196, 72197</u>	<u>Last Revised Date: April 2021</u>
<u>Guideline Number: NIA CG 037</u>	<u>Implementation Date: January 2022</u>

Note: There is no MRI Abdomen/Pelvis combo (comparable to a CT Abdomen/Pelvis) such that if imaging of both the abdomen and pelvis are indicated, two separate exams (and authorization) are required (i.e., MRI Abdomen and MRI Pelvis)

### INDICATIONS FOR PELVIC MRI: (

~~We should add something about overlapping imaging~~  
[Click here for Fetal MRI indications\)](#)

### Initial pelvic imaging for staging of prostate cancer:

- ~~• (High Risk and above (T3a or higher, PSA >20\*, Gleason 8-10)~~
- ~~•~~
- Intermediate Risk (T2b-T2c or PSA 10-20\* or Gleason 7) when Nomogram predicts >10% probability of lymph node involvement (MSKCC/Kattan is the nomogram recommended by NCCN 2021)

\* National Imaging Associates, Inc. (NIA) is a subsidiary of Magellan Healthcare, Inc.

\*In patients who have been on a 5-alpha reductase inhibitor (such as ~~P~~roscar) in the past 12 months, an “adjusted PSA” should be used. To adjust, multiply PSA by a factor of 2 (i.e., PSA 6 on finasteride adjusts to a PSA of 12)

~~NCCN, 2019)~~

~~For prostate cancer when intermediate risk or greater and prostate specific antigen (PSA) level  $\geq 10$  ng/mL, or biopsy GS  $\geq 7$ , or clinically advanced disease (T2b, T2c, T3, or T4) AND nomogram (e.g., Partin, Cancer of Prostate Risk Assessment (CAPRA)) indicating probability of lymph node involvement  $>10\%$ ) (NCCN, 2019)~~

### **Known prostate cancer for workup of recurrence and response to treatment:** (NCCN, 2019)

- Initial treatment by active surveillance (asymptomatic very low, or low or intermediate risk with expected patient survival  $\geq 10$  years):
  - Initial multiparametric MRI (mpMRI) for patients who chose active surveillance
  - mpMRI to be repeated no more than every 12 months unless clinically indicated
- Initial treatment by radical prostatectomy:
  - Failure of PSA to fall to undetectable level or PSA detectable and rising on at least 2 subsequent determinations
- Initial treatment radiation therapy:
  - Post-radiation therapy (Post-RT) rising PSA or positive digital exam and is candidate for local therapy

### **Indication for prostate MRI (suspected prostate cancer)**

(Bjurlin, 2018, 2020; Borofsky, 2018; EAU, 2018; Elkhoury, 2019; NCCN, 2021)

~~(Bjurlin, 2018; Borofsky, 2018; EAU, 2018; Elkhoury, 2019)~~

~~● Rising or persistent elevated PSA (with lab reports on 2 or more separate days); OR~~

~~● Suspicious digital rectal exam (DRE)~~

~~AND~~

~~● At least 15-year life expectancy AND negative prior biopsy~~

~~— Negative prior biopsy AND 15+ year life expectancy AND EITHER:~~

~~— Rising or persistent elevated PSA (with lab reports on 2 or more separate days); OR~~

~~— Suspicious digital rectal exam (DRE) (Bjurlin, 2018; Borofsky, 2018; EAU, 2018; Elkhoury, 2019)~~

~~● Prior to prostate biopsy when notes indicate that biopsy is planned (Fulgham Alexander, et al 2019)~~

~~● -In individuals with previous negative biopsy and ongoing concerns of increased risk of prostate cancer (i.e., rising or persistent elevated PSA with lab reports on 2 or more separate days OR suspicious digital rectal exam (DRE))~~

**Note: Prostate MRI should not replace biopsy nor be used to determine if biopsy is necessary.**  
~~(current evidence does not support the use of MRI in order to determine if a patient needs a biopsy or if a biopsy can be avoided)~~

### Evaluation of suspicious or known mass/tumors

- Initial evaluation of suspicious pelvic masses/tumors found only in the pelvis by physical exam and ultrasound has been performed (ACR, 2013, 2014)
- Further evaluation of abnormality seen on ultrasound (US) or when US is inconclusive (ACR, 2013, 2014)-
- Surveillance: One follow-up exam to ensure no suspicious change has occurred in a tumor in the pelvis. No further surveillance ~~CTMR~~ unless tumor(s) are specified as highly suspicious or change was found on exam or last follow-up imaging.
- Initial staging of known cancer-
  - ~~Initial staging of pre-treatment endometrial cancer for all tumor grades (ACR, 2020)~~
- Follow-up of known cancer (Bourgioti, 2016; NCCN, 2019):
  - ~~Follow-up of known cancer of~~ Of patient undergoing active treatment within the past year-
  - ~~Known cancer with~~ With suspected pelvic metastasis based on a sign, symptom, (e.g., anorexia, early satiety, intestinal obstruction, night sweats, pelvic pain, weight loss, vaginal bleeding) ~~(e.g. anorexia, early satiety, intestinal obstruction, night sweats, pelvic pain, weight loss, vaginal bleeding)~~ or an abnormal lab value (alpha-fetoprotein, CEA, CA 19-9, p53 mutation) ~~(alpha-fetoprotein, CEA, CA 19-9, p53 mutation)~~.

### Indication for combination studies for the initial pre-therapy staging of cancer, OR active monitoring for recurrence as clinically indicated OR evaluation of suspected metastases-

- ≤ 5 concurrent studies to include CT or MRI of any of the following areas as appropriate depending on the cancer: Neck, Abdomen, Pelvis, Chest, Brain, Cervical Spine, Thoracic Spine or Lumbar Spine

### For evaluation of suspected infection or inflammatory disease and after preliminary imaging (such as CT, US, or nuclear medicine) ~~(such as CT, or US, or nuclear medicine)~~ has been performed or is contraindicated (includes MR urography (MRU) which includes abdomen MRI when indicated)

(ACR, 2013; Cartwright, 2015)

- Suspected perianal fistula
- Suspected infection (based on elevated WBC, fever, anorexia, or nausea and vomiting) in the pelvis-
- For suspected urethral stricture or periurethral pathology (Aldamanhori, 2018); ~~Lv, 2016)~~

### For evaluation of known infection or inflammatory disease follow-up-

(ACR, 2013; 2014; Vogel, 2016)

- Any known infection that is clinically suspected to have created an abscess in the pelvis and preliminary imaging has been performed or is contraindicated-

- Any history of fistula limited to the pelvis that requires re-evaluation or is suspected to have recurred-
- For patients with recurrent fistula-in-ano or perianal Crohn's disease
- Abnormal fluid collection seen on prior imaging that needs follow-up evaluation and is limited to the pelvis-

**For evaluation of suspected inflammatory bowel disease or follow-up (includes MR enterography and can also approve Abdomen MRI/MRE):**

- For suspected **inflammatory bowel disease** (Crohn's disease **or ulcerative colitis**) with abdominal pain **AND, AND one of the following (ACR, 2019; Arif-Tiwari, 2019; Lichtenstein, 2018):**
  - ~~Cehronic~~ **diarrhea-diarrhea,**
  - ~~-or Bb~~ **bloody diarrhea, -AND fatigue, or when there is a**
- **H**igh clinical suspicion after complete work up including physical exam, labs, endoscopy with biopsy (ACR, 2019; Arif-Tiwari, 2019; Lichtenstein, 2018; **Rubin, 2019**)-
- ~~For ulcerative colitis that is suspected clinically, however abdominal symptoms (e.g., abdominal pain, diarrhea, or hematochezia) are not explained by endoscopy (Rubin, 2019)~~
- For MR enterography (MRE) if CT or MRI of the abdomen and pelvis are inconclusive-
- ~~Known inflammatory bowel disease (Crohn's or ulcerative colitis) with recurrence or worsening signs/symptoms (e.g., abdominal pain, diarrhea, or hematochezia) (e.g., abdominal pain, diarrhea, or hematochezia) requiring re-evaluation, or for monitoring therapy (ACR, 2019)~~

**For suspected or known hernia:**

- For pelvic pain due to a suspected occult, spigelian, or incisional hernia when **p-p** physical exam **or-and** prior imaging are non-diagnostic or equivocal or if requested as a preoperative study
  - ~~Suspected athletic pubalgia (sports hernia) in a patient with persistent groin pain that occurs with exertion, who has not responded to conservative treatment for four weeks, when other imaging is inconclusive (Lee, 2017; Paksoy, 2016).~~
  - For confirming diagnosis of a recurrent hernia when ultrasound is negative or nondiagnostic
  - **Hernia with suspected complications (e.g., bowel obstruction or strangulation, or non-reducible) based on symptoms (e.g., diarrhea, hematochezia, vomiting, severe pain, or guarding), physical exam (guarding, rebound)- or prior imaging (Halligan, 2018).** ~~For hernia with suspected complications (e.g., Bowel obstruction or strangulation or non-reducible) based on symptoms (e.g., diarrhea, hematochezia, vomiting, severe pain, or guarding)~~
  -

—Suspected athletic pubalgia (sports hernia) in a patient with persistent groin pain that occurs with exertion, who has not responded to conservative treatment for four weeks, when other imaging is inconclusive (Lee, 2017; Paksoy, 2016).

#### Indications for Musculoskeletal Pelvic MRI:

- Initial evaluation of suspicious mass/tumor of the bones, muscles or soft tissues of the pelvis found on an imaging study, and needing clarification, or found by physical exam and ~~remains non-diagnostic~~ after x-ray or ultrasound ~~is completed-is completed.~~
- Evaluation of suspected fracture and/or injury when initial imaging is ~~completed completed~~ ~~inconclusive or needs further evaluation;~~ or for ~~confirmed~~ stress (fatigue) fracture for “return to play” evaluation (ACR, 2016).
- For evaluation of known or suspected aseptic/avascular necrosis of hip(s) after completion of initial x-ray (ACR, 2015).
- ~~Known or suspected~~ **Known or suspected** sacroiliitis (infectious or inflammatory) after ~~abnormal abnormal completion of initial~~ x-ray (ACR, 2016; Jans, 2014).
- Sacroiliac Joint Dysfunction when there is (Jans, 2014):
  - Persistent back and/or sacral pain unresponsive to four (4) weeks of conservative treatment, received within the past six (6) months, including physical therapy or physician supervised home exercise plan (HEP).
- For evaluating the lumbosacral plexus (ACR, 2016; Muniz-Neto, 2018):
  - To confirm involvement in symptomatic patients with known tumor
  - To assess extent of injuries in the setting of pelvic trauma
  - To exclude the presence of masses in patients with unilateral changes, or inconclusive or abnormal findings on EMG when there are persistent symptoms
  - For evaluation when lumbar spine MRI is suspicious or indeterminate
- For suspicion of pudendal neuralgia in the setting of chronic pelvic pain with genital numbness and erectile dysfunction when other causes have been ruled out (see ~~comments~~ **Background below** regarding diagnosis) (Wadhwa, 2016)
- For suspicion of meralgia paresthetica when prior testing is inconclusive (diagnostic nerve block; electrodiagnostic testing; AND somatosensory evoked potentials) (Ally, 2019; Cheatham, 2013)
- Persistent Pain:
  - For evaluation of persistent pain unresponsive to four (4) weeks of conservative treatment received within the past six (6) months.
  - For suspected piriformis syndrome after failure of 4 weeks conservative treatment (Hoon Ro, 2018)
- For further evaluation of congenital anomalies of the sacrum and pelvis and initial imaging has been performed.

#### Other Indications for a Pelvic MRI:

- **Pelvic pain not explained by previous imaging/preprocedure (ACR, 2018)**

- Appropriate laboratory testing (chemistry profile, complete blood count, and urinalysis) and initial imaging, such as ultrasound
- ~~— Subacute or chronic Pelvic pain not explained by previous imaging/preprocedure (ACR, 2018)~~
- ~~— Appropriate laboratory testing (chemistry profile, complete blood count, and urinalysis) and initial imaging such as ultrasound~~
- For location or evaluation of undescended testes in adults and in children, including determination of location of testes, if ordered by a specialist (Kolon, 2014)
- For evaluation and characterization of uterine and adnexal masses, (e.g., fibroids, ovaries, tubes, and uterine ligaments) or congenital uterine or renal abnormality where ultrasound has been done previously (ACR, 2018).
- For evaluation of abnormal uterine bleeding when ultrasound findings are indeterminate (ACR 2020)
  - Age ≤ 50 – Vascular stalk or focal doppler signal on US
  - Age > 50 – Thickened endometrium, vascular stalk or focal doppler signal on US
  - ~~— For evaluation of abnormal uterine bleeding when ultrasound findings are indeterminate (ACR, 2020)~~
  - ~~— Age ≤ 50 – Vascular stalk or focal doppler signal on US~~
  - ~~Age > 50 – Thickened endometrium, vascular stalk or focal doppler signal on US~~
- 
- For evaluation of uterus prior to and after embolization (MRA preferred) (Deshmukh, 2012).
- For evaluation of endometriosis when preliminary imaging has been completed or to follow up known endometriosis (ACR, 2012; Siegelman, 2012)
- For further evaluation of suspected adenomyosis when ultrasound is inconclusive (Cunningham, 2018), such as the following:
  - Uterine abnormality on US
    - Anechoic spaces/cysts in myometrium
    - Heterogeneous echotexture
    - Obscured endometrial/myometrial border
    - Sub-endometrial echogenic linear striations
    - Thickening of the transition zone
    - Uterine enlargement
    - Uterine wall thickening
- ~~— For further evaluation of suspected adenomyosis when ultrasound is inconclusive (Cunningham, 2018) such as the following:~~
- ~~— Uterine abnormality on US~~
- ~~— Anechoic spaces/cysts in myometrium~~
- ~~— Heterogenous echotexture~~
- ~~— Obscured endometrial/myometrial border~~
- ~~— Sub-endometrial echogenic linearlinear striations~~
- ~~— Thickening of the transition zone~~
- ~~— Uterine enlargement~~

● ~~Uterine wall thickening~~

- Prior to uterine surgery if there is abnormality suspected on prior ultrasound
- For suspected placenta accreta or percreta when ultrasound is indeterminate (Kilcoyne, 2017)
- For further assessment of a scrotal or penile mass when ultrasound is inconclusive (Kirkham, 2012; Parker, 2015)
- For investigation of a malfunctioning penile prosthesis
- Suspected urethral diverticula and other imaging is inconclusive (Dwarkasing, 2011)  
(MRI may be indicated without prior ultrasound in limited situations as suggested, such as when there is compelling evidence suggestive of urethral diverticulum (i.e. ostia on cystoscopy or tender cystic lesion on anterior vaginal wall overlying the urethra) or for surgical planning.)~~pelvic~~

● ~~For evaluation of adenomyosis when ultrasound is equivocal, especially in the case of suspected focal adenomyoma when it will help determine if surgery is indicated (Li, 2018)~~

- For suspected pelvic congestion syndrome in women~~women~~ patients with chronic pelvic pain when other imaging is non-diagnostic (Knuttninen, 2015)
- For suspected patent urachus or other urachal abnormalities when ultrasound is ~~non~~non-diagnostic (Buddha, 2019; Villavicencio, 2016)
- For evaluation of suspected pelvic floor weakness in women with functional disorders, such as urinary or fecal incontinence, obstructed defecation, and pelvic organ prolapse (Garcia del Sato, 2014)
- MR defecography for suspected structural cause of defecatory outlet obstruction to confirm diagnosis if other testing is equivocal (anorectal manometry and balloon expulsion testing) (Wald, 2014)
- For evaluation of enlargement of organ abnormality seen on previous imaging - to provide an alternative to an indeterminate or inconclusive ultrasound
- For diffuse, unexplained lower extremity edema with negative or inconclusive ultrasound (~~Hoshino, 2016~~)
- For May-Thurner syndrome (MRV preferred)
- For further evaluation of an isolated right varicocele with additional signs and symptoms (e.g., jaundice, lymphadenopathy, night sweats or weight loss) that suggest malignancy or suspicious prior imaging findings (Gleason, 2019)
- Surveillance MRI (include abdomen) every 2-3 years for patients with Hereditary Paraganglioma syndromes Type 1-5 (Benn, 2015)
- In hematospermia in men over 40, if ~~t~~transrectal ultrasound is negative or inconclusive (Allen, 2017)

**Pre-operative evaluation:**

- For diagnostic purposes prior to pelvic surgery or procedure

**PFor post-operative/procedural evaluation:**



- Follow-up of known or suspected post-operative complication involving the hips or the pelvis (Davis, 2016; Yanny, 2012) within six months.
- A follow-up study to help evaluate a patient's progress after treatment, procedure, intervention, or surgery. Documentation requires a medical reason that clearly indicates why additional imaging is needed.

**Note:** If an Abdomen/Pelvis MRI is indicated and the Abdomen MRI has already been approved, then the Pelvis MRI may be approved.

**Fetal MRI (CPT codes 74712-74713)** - To better define or confirm a known for suspected abnormality of the fetus after ultrasound has been performed during the second trimester (Prayer, 2017) or when fetal surgery is planned and/or to make a decision about therapy, delivery or to advise the family about prognosis (ACR-SPR, 2015; SPR, 2011). Also includes evaluation of the maternal pelvis and placenta.

## BACKGROUND

Magnetic resonance imaging of the pelvis is a noninvasive technique for the evaluation, assessment of severity, and follow-up of diseases of the male and female pelvic organs. MRI provides excellent contrast of soft tissues and provides multiplanar and 3D depiction of pathology and anatomy. Patients undergoing MRI do not have exposure to ionizing radiation or iodinated contrast materials. MRI techniques utilize body coils to image the entire pelvis or endoluminal coils for evaluation of the rectum, prostate, and genitourinary system.

## OVERVIEW

### PI-RADS Assessment Categories for Prostate Cancer:

(ACR, 2019)

The assignment of a ~~PI~~**PI**-RADS category is based on mpMRI findings only and does not incorporate other factors, including PSA testing, DRE (digital rectal exam), or clinical history.

PIRADS 1 – Very low (clinically significant cancer is highly unlikely to be present)

PIRADS 2 – Low (clinically significant cancer is unlikely to be present)

PIRADS 3 – Intermediate (the presence of clinically significant cancer is equivocal)

PIRADS 4 – High (clinically significant cancer is likely to be present)

PIRADS 5 – Very high (clinically significant cancer is highly likely to be present)

**\*Conservative Therapy** ~~:- Conservative therapy (spine)~~ should include a multimodality approach consisting of a **combination of active and inactive components**. Inactive components, such as rest, ice, heat, modified activities, medical devices, acupuncture and/or stimulators, medications, injections (epidural, facet, bursal, and/or joint, not including trigger



point), and diathermy can be utilized. Active modalities may consist of physical therapy, a ~~physician~~ physician-supervised home exercise program\*\*, and/or chiropractic care.

**\*\*Home Exercise Program - (HEP)/Therapy** – the following elements are required to meet guidelines for completion of conservative therapy (ACR, 2015; Last, 2009):

- Information provided on exercise prescription/plan AND
- Follow up with member with documentation provided regarding lack of improvement (failed) after completion of HEP (after suitable 4-4-week period), or inability to complete HEP due to physical reason- i.e., increased pain, inability to physically perform exercises. (Patient inconvenience or noncompliance without explanation does not constitute “inability to complete” HEP).
- Dates and duration of failed PT, ~~physician~~ physician-supervised HEP, or chiropractic treatment should be documented in the original office notes or an addendum to the notes.

**MRI and Undescended Testes** – The most common genital malformation in boys is undescended testis. In one series, 70% of undescended testes are palpable. ~~Dand~~ despite the advances in ultrasound technology, ultrasound cannot reliably identify intra-abdominal testes, which comprise 20% of all undescended testes (Tasian, 2011). The timely management of undescended testis is important to potentially minimize the risk of infertility and lessen the risk of malignancy. MRI is used as a diagnostic tool in the detection of undescended testes and can reveal information for both anatomic and tissue characterization. It is noninvasive, non-ionizing, and can obtain multiplanar images.

**MRI and Adnexal Masses** – MRI is used in the evaluation of adnexal masses. It can identify and characterize different neoplastic and nonneoplastic abnormalities, e.g., exophytic leiomyoma, endometrioma, dermoid cyst, and ovarian edema. It is a useful adjunct when sonography is inconclusive in the evaluation of adnexal masses.

**MRI and Endometriosis** – MRI manifestations of endometriosis vary including endometrioma, peritoneal endometrial implant, adhesion, and other rare features. The data obtained from imaging must be combined with clinical data to perform preoperative assessment of endometriosis.

**MRI and Lumbosacral Plexopathy** - Complete lumbar (L1-L4) or sacral plexopathy (L5-S3) may present with weakness, sensory loss, and flaccid loss of tendon reflexes. Clinical diagnosis is confirmed by EMG. Acute and chronic plexopathies may be caused by nerve sheath tumors; infectious, autoimmune, hereditary, or idiopathic neuropathies; ~~or~~ extrinsic compression; or trauma (ACR, 2016). There is no CPT® code specifically for imaging of the LS plexus. Pudendal neuralgia may be considered in chronic pain patients who meet the Nantes criteria: pain in the area innervated by the pudendal nerve, pain more severe with sitting, pain that does not awaken the patient from sleep, pain with no objective sensory impairment, and pain relieved by pudendal block. All five criteria must be met for diagnosis (Wadhwa, 2016).

**MRI and Prostate Cancer** – Although prostate cancer is the second leading cause of cancer in men, ~~the majority of most~~ cases do not lead to a prostate ~~cancer-cancer~~-related death. Aggressive treatment of prostate cancer can have side effects, such as incontinence, rectal injury, and impotence. It is very important to do an evaluation ~~which-that~~ will assist in making decisions about therapy or treatment. MRI can non-invasively assess prostate tissue, functionally and morphologically. MRI evaluation may use a large array of techniques, e.g., T1-weighted images, T2-weighted images, and dynamic contrast enhanced T1-weighted images.

**Prostate Cancer** – MRI is not recommended in patients with suspected cancer but prior negative biopsy because MRI alone can miss up to 26% of clinically significant cancers that would be detected on TRUS biopsy (Borofsky, 2018). Patients with suspected prostate cancer should first undergo a systematic biopsy and if that fails to demonstrate tumor, an MRI can then be obtained to guide future biopsy attempts (Bjurlin, 2018; ~~JAMA~~Elkhoury, 2019).

Per NCCN, 2019, for asymptomatic patients with prostate cancer, in very low, low, or intermediate groups with life expectancy  $\leq 5$  years, no further treatment or ~~work-work~~-up indicated (unless the patient becomes symptomatic). Active surveillance is indicated if life expectancy is determined to be  $\geq 10$  years.

**MRI and Rectal Cancer** – MRI is used in the evaluation of rectal cancer to visualize not only the intestinal wall but also the surrounding pelvic anatomy. MRI is an excellent imaging technique due to its high soft-tissue contrast, powerful gradient system, and high resolution. It provides accurate evaluation of the topographic relationship between lateral tumor extent and the mesorectal fascia.

**Imaging of hernias**~~s~~ – Most hernias are diagnosed clinically with imaging recommended for the diagnosis of occult hernias or in the evaluation of hernia complications, such as bowel obstruction or strangulation. To detect occult hernias, ultrasound is a ~~first-first~~-line study with a sensitivity of 86% and specificity of 77%, compared to 80% sensitivity and 65% specificity for CT (Robinson, 2013). According to Miller et al., “Magnetic resonance imaging is generally not considered a first- or even second-line evaluation modality for hernias...” (Miller, 2014). Both MRI and US can be valuable for diagnosing pathology in athletes with groin pain when a sports hernia is suspected. Pain usually occurs with exertion with tenderness over the pubic symphysis or tubercle and exquisite tenderness on direct palpation of the superficial inguinal ring (positive direct stress test). This term initially denoted a posterior inguinal wall deficiency due to disruption of fascia and/or muscle but more recently given the label “core injury” to also include adductor tendon tears, injury to the aponeurosis of the rectus abdominus and adductor longus tendons, and osteitis pubis (Lee, 2017).

**Elevated CA-125 and pelvic imaging**- There is no evidence that isolated levels of CA-125 with no other clinical or radiologic evidence of pathology is sensitive or specific and should not be performed as an isolated test as it can lead to unnecessary studies and anxiety. It is elevated in

most cases of epithelial ovarian cancer and is used in monitoring response to treatment as an adjunct to pelvic US. ~~CA-CA~~-125 has been shown to be increased in many conditions such as with fibroids, adenomyosis, pancreatic cancer, endometriosis, tuberculosis, and interstitial lung disease, ~~etc~~. MRI is not indicated as a ~~first~~-first-line test (Tahmasebi, 2018).

## POLICY HISTORY

Date	Summary
<u>July 2021</u>	<ul style="list-style-type: none"> <li>• <u>Clarified language in Indication for prostate MRI (suspected prostate cancer) based on updates to Version 2.2021 NCCN guidelines and 2020 publication of updated AUA-SAR SOPs regarding MRI</u></li> </ul>
April 2021	<ul style="list-style-type: none"> <li>• <u>Updated the initial imaging for prostate cancer to reflect 2021 NCCN changes and “adjusted PSA”</u></li> <li>• <u>Revised indication for prostate MRI (suspected prostate cancer) to clarify criteria related to a negative prior biopsy and added criteria for when imaging is appropriate prior to biopsy</u></li> <li>• <u>Included criteria for ultrasound abnormalities for adenomyosis</u></li> <li>• <u>Added limited circumstances when prior imaging is not needed before MRI for the evaluation of urethral diverticula</u></li> </ul>
<u>May 2020</u>	<ul style="list-style-type: none"> <li>• <u>Mention MRU which includes MRI abd</u></li> <li>• <u>Perianal fistula including with Crohn’s</u></li> <li>• <u>Urethral eval</u></li> <li>• <u>Added section on MRE for IBD</u></li> <li>• <u>Added section on Lumbosacral plexus, pudendal neuralgia, maralgia paresthetica, piriformis syndrome</u></li> <li>• <u>Added separate section on hernia including sports hernia</u></li> <li>• <u>Added abnormal uterine bleeding; adenomyosis; pelvic floor weakness; urachal anomalies; MR defecography; surveillance for paraganglioma syndromes; hematospermia; LE edema; right varicocele; May-Thurner</u></li> <li>• <u>Added the Fetal MR GL to page</u></li> <li>• <u>Comment section on Lumbar plexopathy, sports hernia, elevated CA-125</u></li> </ul>
<u>June 2019</u>	<ul style="list-style-type: none"> <li>• <u>Added the following indications:</u> <ul style="list-style-type: none"> <li>○ <u>rising or persistent elevated PSA OR suspicious DRE and at least 15 yr life expectancy and negative prior biopsy</u></li> <li>○ <u>suspected perianal fistula</u></li> </ul> </li> </ul>

	<ul style="list-style-type: none"> <li>○ <u>6 months time specification for f/u of known or suspected post-operative complication involving hips or pelvis</u></li> <li>○ <u>for confirmed stress (fatigue) fracture for “return to play” evaluation</u></li> <li>○ <u>post operative complications after pelvic floor surgery</u></li> <li>○ <u>For known prostate cancer: Initial treatment by active surveillance w/initial mpMRI and mpMRI to be repeated no more than every 12 months unless clinically indicated</u></li> <li>○ <u>suspected placenta accrete or percreta when US is indeterminate</u></li> <li>○ <u>further assessment of a scrotal or penile mass when ultrasound is inconclusive</u></li> <li>○ <u>investigation of a malfunctioning penile prosthesis</u></li> <li>○ <u>suspected urethral diverticula and other imaging is inconclusive</u></li> <li>○ <u>evaluation of adenomyosis when ultrasound is equivocal, especially in the case of suspected focal adenomyoma when it will help determine if surgery is indicated</u></li> <li>○ <u>suspected pelvic congestion syndrome in patients with chronic pelvic pain when other imaging is non-diagnostic</u></li> <li>○ <u>suspected patent urachus when ultrasound is non diagnostic</u></li> <li>○ <u>evaluation of enlargement of organ abnormality seen on previous imaging - to provide an alternative to an indeterminate or inconclusive ultrasound</u></li> <li>○ <u>PI-RADS information to background section</u></li> <li>○ <u>Home exercise program information updated to include dates and duration of failed PT and other</u></li> </ul>
--	--

**Review Date:** June 2019

**Review Summary:**

● ~~Added the following indications:~~

- ~~rising or persistent elevated PSA OR suspicious DRE and at least 15-yr life expectancy and negative prior biopsy~~
- ~~suspected perianal fistula~~
- ~~6 months time specification for f/u of known or suspected post-operative complication involving hips or pelvis~~
- ~~for confirmed stress (fatigue) fracture for “return to play” evaluation~~
- ~~post operative complications after pelvic floor surgery~~

- ~~For known prostate cancer: Initial treatment by active surveillance w/initial mpMRI and mpMRI to be repeated no more than every 12 months unless clinically indicated~~
- ~~suspected placenta accrete or percreta when US is indeterminate~~
- ~~further assessment of a scrotal or penile mass when ultrasound is inconclusive~~
- ~~investigation of a malfunctioning penile prosthesis~~
- ~~suspected urethral diverticula and other imaging is inconclusive~~
- ~~evaluation of adenomyosis when ultrasound is equivocal, especially in the case of suspected focal adenomyoma when it will help determine if surgery is indicated~~
- ~~suspected pelvic congestion syndrome in patients with chronic pelvic pain when other imaging is non-diagnostic~~
- ~~suspected patent urachus when ultrasound is non diagnostic~~
- ~~evaluation of enlargement of organ abnormality seen on previous imaging to provide an alternative to an indeterminate or inconclusive ultrasound~~
- ~~PI-RADS information to background section~~
- ~~Home exercise program information updated to include dates and duration of failed PT and other~~

**Review Date:** May 2020

**Review Summary:**

- ~~Mention MRU which includes MRI abd~~
- ~~Perianal fistula including with Crohn's~~
- ~~Urethral eval~~
- ~~Added section on MRE for IBD~~
- ~~Added section on Lumbosacral plexus, pudendal neuralgia, maralgia paresthetica, piriformis syndrome~~
- ~~Added separate section on hernia including sports hernia~~
- ~~Added abnormal uterine bleeding; adenomyosis; pelvic floor weakness; urachal anomalies; MR defecography; surveillance for paraganglioma syndromes; hematospermia; LE edema; right varicocele; May-Thurner~~
- ~~Added the Fetal MR GL to page~~
- ~~Comment section on Lumbar plexopathy, sports hernia, elevated CA-125~~

Review Date: April 2021

Review Summary:

Updated the initial imaging for prostate cancer to reflect 2021 NCCN changes and "adjusted PSA"

~~Revised indication for prostate MRI (suspected prostate cancer) to clarify criteria related to a negative prior biopsy and added criteria for when imaging is appropriate prior to biopsy~~

~~Included criteria for ultrasound abnormalities for adenomyosis~~

~~Added limited circumstances when prior imaging is not needed before MRI for the evaluation of urethral diverticula~~

## REFERENCES

Ahdoot M, Wilbur AR, Reese SE, et al. MRI-targeted, systematic, and combined biopsy for prostate cancer diagnosis. *N Engl J Med*. 2020;382(10):917-928. doi:10.1056/NEJMoa1910038.

Ahmed HU, El-Shater Bosaily A, Brown LC, et al. Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): A paired validating confirmatory study. *Lancet*. 2017;389(10071):815-822. doi:10.1016/S0140-6736(16)32401-1.

Aldamanhori R, Inman R. The treatment of complex female urethral pathology. *Asian J Urol*. 2018;5(3):160-163. doi:10.1016/j.ajur.2018.03.003.

Alexander LF, Oto A, Allen BC, et al. ACR Appropriateness Criteria® lower urinary tract symptoms-suspicion of benign prostatic hyperplasia. *J Am Coll Radiol*. 2019;16(11S):S378-S383. doi:10.1016/j.jacr.2019.05.031.

Allen BC, Coakley FV, et al. ACR Appropriateness Criteria Hematospermia. *J Am Coll Radiol*. 2017; 14:S154-S159.

Ally RM, Velleman MD, et al. Meralgia paresthetica: Now showing on 3T magnetic resonance neurography. *SA J Radiol*. 2019.

American College of Radiology (ACR). ACR Appropriateness Criteria®. <https://acsearch.acr.org/list>. Published 2018; revised 2016.

American College of Radiology (ACR). PI-RADS Prostate Imaging-Reporting and Data System. V2.1. 2019.

American College of Radiology (ACR) and Society for Pediatric Radiology (SPR). ACR-SPR Practice Parameter for the Safe and Optimal Performance of Fetal Magnetic Resonance Imaging (MRI). <https://www.acr.org/-/media/ACR/Files/Practice-Parameters/MR-Fetal.pdf>. Retrieved February 7, 2018.

American Urological Association (AUA) and Society of Abdominal Radiology (SAR). Prostate MRI and MRI-Targeted Biopsy in Patients with Prior Negative Biopsy. Collaborative Initiative of the American Urological Association and the Society of Abdominal Radiology's Prostate Cancer Disease-Focused Panel. <http://www.auanet.org/guidelines/prostate-mri-and-mri-targeted-biopsy>. Published 2016. Retrieved February 7, 2018.

Arif-Tiwari H, Taylor P, Kalb BT, Martin DR. Magnetic resonance enterography in inflammatory bowel disease. *Appl Radiol*. 2019;48(1):9-15.

Behr SC, Courtier JL, Qayyum A. Imaging of Mullerian duct anomalies. *Radiographics*. 2012 Oct; 32(6).



Benn DE, Robinson BG, et al. Clinical manifestations of paraganglioma syndrome types 1-5. *Thamatic Rev.* 2015. <http://erc.endocrinology-journals.org>.

Bitti GT, Argiolas GM, Ballicu N, et al. Pelvic floor failure: MR imaging evaluation of anatomic and functional abnormalities. *RadioGraphics.* 2014; 34(2):429-448. doi: 10.1148/rg.342125050.

Bjurlin MA, Carroll PR, Eggener S, et al. American Urological Association. MRI of the Prostate, Standard Operating Procedure (SOP). 2018. <http://www.auanet.org/guidelines/mri-of-the-prostate-sop>. Retrieved February 7, 2018.

**Bjurlin MA, Carroll PR, Eggener S, et al. Update of the standard operating procedure on the use of multiparametric magnetic resonance imaging for the diagnosis, staging and management of prostate cancer. J Urol. 2020;203(4):706-712. doi:10.1097/JU.0000000000000617.**

Bloch BN, Lenkinski RE, Rofskyk NM. The role of magnetic resonance imaging (MRI) in prostate cancer imaging and staging at 1.5 and 3 tesla: The Beth Israel Deaconess Medical Center (BIDMC) approach. *Cancer Biomark.* 2008; 4(4-5):251-262. <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2739836/pdf/nihms124629.pdf>.

~~Brandon CJ, Jacobson JA, Fessell D, et al. Pain beyond the hip: How anatomy predisposes to injury as visualized by musculoskeletal ultrasound and MRI. *AJR Am J Roentgenol.* 2011; 197(5):1190-1197. doi: 10.2214/AJR.10.4890.~~

Borofsky S, George AK, Gaur S, et al. What are we missing? False-negative cancers at multiparametric MR imaging of the prostate. *Radiology.* January 2018; 286(1):186-195. <https://www.ncbi.nlm.nih.gov/pubmed/29053402>. Retrieved February 7, 2018.

Bourgioti C, Chatoupis K, Mouloupoulos LA. Current imaging strategies for the evaluation of uterine cervical cancer. *World J Radiol.* April 28, 2016; 8(4):342-354. doi: 10.4329/wjr.v8.i4.342.

Brandon CJ, Jacobson JA, Fessell D, et al. Pain beyond the hip: How anatomy predisposes to injury as visualized by musculoskeletal ultrasound and MRI. *AJR Am J Roentgenol.* 2011; 197(5):1190-1197. doi: 10.2214/AJR.10.4890.

Buddha S, Menias CO, et al. Imaging of Urachal anomalies. *Abdom Radiol.* 2019; 44:3978-3989.

Cartwright SL, Knudson MP. Diagnostic imaging of acute abdominal pain in adults. *Am Fam Physician.* April 1, 2015; 91(7):452-459. <https://www.aafp.org/afp/2015/0401/p452.html>. Retrieved February 7, 2018.

Cheatham SW, Kilber MJ, et al. Meralgia Paresthetica: A Review of the Literature. *Int J Sports Phys Ther*. 2013; 8(6).

Cunningham RK, Horrow MH, et al. Adenomyosis: A Sonographic Diagnosis. *Radiographics*. 2018;38(5)

Davis D, Morrison JJ. Hip arthroplasty pseudotumors: Pathogenesis, imaging, and clinical decision making. *J Clin Imaging Sci*. 2016; 6:17.  
<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4863402/>. Retrieved February 8, 2018.

Deshmukh S, Gonsalves CF, Guglielmo FF, et al. Role of MR imaging of uterine leiomyomas before and after embolization. *RadioGraphics*. 2012; 32:E251-E281.  
<http://pubs.rsna.org/doi/pdf/10.1148/rg.326125517>. Retrieved February 7, 2018.

Dwarkasing RA, Dinkelaar W, Hop WC, et al. MRI evaluation of urethral diverticula and differential diagnosis in symptomatic women. *AJR*. 2011 Sept; 197(3):676-82.

Elkhoury FF, Felker ER, Kwan L, et al. Comparison of targeted vs systematic prostate biopsy in men who are biopsy naïve: The prospective assessment of image registration in the diagnosis of prostate cancer (PAIREDCAP) study. *JAMA Surg*. June 12, 2019.

European Association of Urology (EAU). EAU-ESTRO-ESUR-SIOG Guidelines on prostate cancer. 2018.

Garcia del Sato L, de Miguel Criado J, Aguilera del Hoyo LF, et al. MR Imaging-based assessment of the female pelvic floor. *Radiographics*. 2014; 34:1417-1439.

Gleason A, Bishop K, et al. Isolated right varicocele: Is Further Workup Necessary. *AJR*. 2019; 212(4).

**Halligan S, Parker SG, Plumb AAO, et al. Use of imaging for pre- and post-operative characterisation of ventral hernia: Systematic review. *Br J Radiol*. 2018;91(1089):20170954. doi:10.1259/bjr.20170954.**

Hoon Ro T, Edmonds L. Diagnosis and management of piriformis syndrome: A rare anatomic variant analyzed by magnetic resonance imaging. *J Clin Imaging Sci*. 2018; 8:6.

Jans L. MRI of the SI joints commonly shows non-inflammatory disease in patients clinically suspected of sacroiliitis. *Eur J Radiol*. January 2014; 83(1):179-184.  
<https://www.ncbi.nlm.nih.gov/pubmed/24168927>. Retrieved February 7, 2018.

Jegannathan D, Venkatraman I. Magnetic resonance imaging of classified and unclassified Müllerian duct anomalies: Comparison of the American Society for Reproductive Medicine and

the European Society of Human Reproduction and Embryology classifications. *SA J Radiol*. 2018 Apr; 22(1).

Jhaveri KS, Hosseini-Nik H. MRI of rectal cancer: An overview and update on recent advances. *AJR*. 2015 Jul; 205(1):W42-55. <https://www.ajronline.org/doi/full/10.2214/AJR.14.14201>.

**Kasivisvanathan V, Rannikko AS, Borghi M, et al. MRI-targeted or standard biopsy for prostate-cancer diagnosis. *N Engl J Med*. 2018;378(19):1767-1777. doi:10.1056/NEJMoa1801993.**

Kilcoyne A, Shenoy-Bhangle AS, Roberts DJ, et al. MRI of placenta accreta, placenta increta and placenta percreta: Pearls and pitfalls. *AJR*. 2017 Jan; 208(1):214-21.

Kirkham A. MRI of the penis. *Br J Radiol*. 2012 Nov; 85(spec issue1):S86-S93.

**Klotz L, Chin J, Black PC, et al. Comparison of multiparametric magnetic resonance imaging-targeted biopsy with systematic transrectal ultrasonography biopsy for biopsy-naïve men at risk for prostate cancer: A phase 3 randomized clinical trial. *JAMA Oncol*. 2021;7(4):534-542. doi:10.1001/jamaoncol.2020.7589.**

Knutтинен MG, Xie K, Jani A, et al. Pelvic venous insufficiency: Imaging diagnosis, treatment approaches, and therapeutic issues. *AJR*. 2015 Feb; 204(2):448-58.

Kolon TF, Herndon CD, Baker LA, et al. Evaluation and treatment cryptorchidism: AUA guideline. *J Urol*. 2014 Aug; 192(2):337-45.

Koulouris G. Imaging review of groin pain in elite athletes: An anatomic approach to imaging findings. *AJR Am J Roentgenol*. 2008; 191:962-972.

Lassandro F, Iasiello F, Pizza NL, et al. Abdominal hernias: Radiological features. *World J Gastrointest Endosc*. 2011 Jun; 3(6):110-117.

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3158902/>. Retrieved February 8, 2018.

Lee SC, Endo Y, Potter HG. Imaging of groin pain: magnetic resonance and ultrasound imaging features. *Sports Health*. 2017; 9(5):428-435.

Li J-J, Chung JPW, Wang S, et al. The investigation and management of adenomyosis in women who wish to improve or preserve fertility. *BioMed Res Internat*. 2018; 1:1-12.

**Lichtenstein GR, Loftus EV, Isaacs KL, Regueiro MD, Gerson LB, Sands BE. ACG clinical guideline: Management of Crohn's disease in adults. *American Journal of Gastroenterology*. 2018;113(4):481-517. doi:10.1038/ajg.2018.27.**

Marks L, Young S, Natarajan S. MRI-ultrasound fusion for guidance of targeted prostate biopsy. *Curr Opin Urol*. 2013; 23(1):43-50. <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3581822/>.

Meermeier NP, Foster BR, Liu JJ, et al. Impact of direct MRI-guided biopsy of the prostate on clinical management. *AJR*. 2019 Aug; 213(2):371-76.

Miller J, Cho J, Michael MJ, et al. Role of imaging in the diagnosis of occult hernias. *JAMA Surg*. October 2014; 149(10):1077-1080. doi: 10.1001/jamasurg.2014.484. <https://jamanetwork.com/journals/jamasurgery/fullarticle/1893806>. Retrieved February 15, 2018.

Muniz Neto FJ, Kihara Filho EN, et al. Demystifying MR Neurography of the lumbosacral plexus: from protocols to pathologies. *Biomed Res Inter*. 2018.

National Comprehensive Cancer Network (NCCN). Guidelines. [https://www.nccn.org/professionals/physician\\_gls/default.aspx](https://www.nccn.org/professionals/physician_gls/default.aspx). Retrieved February 7, 2018.

**National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines): Prostate Cancer Early Detection Version 2.2021. Published July 14, 2021. Accessed July 20, 2021.**

~~[https://www.nccn.org/professionals/physician\\_gls/pdf/prostate\\_detection.pdf](https://www.nccn.org/professionals/physician_gls/pdf/prostate_detection.pdf) National Comprehensive Cancer Network (NCCN). Guidelines v.2.2017 Prostate Cancer Updates. [https://www.nccn.org/professionals/physician\\_gls/pdf/prostate.pdf](https://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf). Retrieved February 7, 2018.~~

~~National Comprehensive Cancer Network (NCCN). Clinical Practice Guidelines in Oncology: Prostate Cancer. v2.2019. Fort Washington, PA: NCCN, 2019. Accessed May 6, 2019.~~

National Comprehensive Cancer Network (NCCN). Guidelines - Basal Cell Skin Cancer. v.2.2018. [https://www.nccn.org/professionals/physician\\_gls/pdf/nmsc.pdf](https://www.nccn.org/professionals/physician_gls/pdf/nmsc.pdf). Retrieved February 7, 2018.

National Comprehensive Cancer Network (NCCN). Guidelines - Melanoma. v.2.2018. [https://www.nccn.org/professionals/physician\\_gls/pdf/melanoma.pdf](https://www.nccn.org/professionals/physician_gls/pdf/melanoma.pdf). Retrieved February 7, 2018.

National Comprehensive Cancer Network (NCCN). NCCN Imaging Appropriate Use Criteria (NCCN Imaging AUC). 2019. <https://www.nccn.org/professionals/imaging/default.aspx>.

O'Malley RB, Al-Hawary MM, Kaza RK, et al. Rectal imaging: Part 2, perianal fistula evaluation on pelvic MRI: What the radiologist needs to know. *AJR*. 2012 Jul; 199(1):W43-53.

Ostlere S. How to image metal-on-metal prostheses and their complications. *AJR Am J Roengenol.* 2011; 197:558-567. doi: 10.2214/AJR.11.6840.

Paksoy M, Sekman O. Sportsmen hernia: the review of current diagnosis and treatment modalities. *Turkish J Surg.* 2016; 32(2):122-129.

Parker RA, Menias CO, Quazi R, et al. MR imaging of the penis and scrotum. *Radiographics.* 2015 Jul-Aug; 35(4):1033-50.

**Prayer D, Malinge G, Brugger PC, et al. ISUOG Practice Guidelines: Performance of fetal magnetic resonance imaging. *Ultrasound Obstet Gynecol.* 2017;49(5):671-680. doi:10.1002/uog.17412.**

Reese AC, Pierorazio PM, Han M, et al. Contemporary evaluation of the National Comprehensive Cancer Network prostate cancer risk classification system. *Urology.* 2012; 80(5):1075-9.

Robinson A. A systematic review and meta-analysis of the role of radiology in the diagnosis of occult inguinal hernia. *Surg Endosc.* January 2013; 27(1):11-18.

**Rouvière O, Puech P, Renard-Penna R, et al. Use of prostate systematic and targeted biopsy on the basis of multiparametric MRI in biopsy-naïve patients (MRI-FIRST): A prospective, multicentre, paired diagnostic study. *Lancet Oncol.* 2019;20(1):100-109. doi:10.1016/S1470-2045(18)30569-2.**

**Rubin DT, Ananthakrishnan AN, Siegel CA, Sauer BG, Long MD. ACG clinical guideline: Ulcerative colitis in adults. *Am J Gastroenterol.* 2019;114(3):384-413. doi:10.14309/ajg.000000000000152.**

Siegelman ES, Oliver ER. MR imaging of endometriosis: Ten imaging pearls. *RadioGraphics.* 2012; 32:1675-1691. <http://pubs.rsna.org/doi/pdf/10.1148/rg.326125518>. Retrieved February 8, 2018.

Shoji S, Hiraiwa S, Endo J, et al. Manually controlled targeted prostate biopsy with real-time fusion imaging of multiparametric magnetic resonance imaging and transrectal ultrasound: An early experience. *Int J Urol.* 2015; 22(2):173-178. <http://www.ncbi.nlm.nih.gov/pubmed/25316213>.

Tahmasebi F, Nath R, et al. Incidental finding of raised ca-125: A cause for concern? *Crit Care Obstet Gynecol.* 2018; 5(1).

Tasian G, Copp HL, Baskin LS. Diagnostic imaging in cryptorchidism: Utility, indications, and effectiveness. *J Pediatr Surg*. December 2011; 46(12):2406-2413.  
<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3712862/>. Retrieved February 7, 2018.

**Thompson IM, Goodman PJ, Tangen CM et al. The influence of finasteride on the development of prostate cancer. *N Engl J Med* 2003; 349: 215.**

Tosoian JJ, Chappidi M, Feng Z et al. Prediction of pathological stage based on clinical stage, serum prostate-specific antigen, and biopsy Gleason score: Partin Tables in the contemporary era. *BJU Int*. 2017; 119(5):676-683.

Trotter SC, Sroa N, Winkelmann RR, et al. A global review of melanoma follow-up guidelines. *J Clin Aesthet Dermatol*. September 2013; 6(9):18-26.  
<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3780800/>. Retrieved February 7, 2018.

**Wadhwa V, Hamid AS, Kumar Y, Scott KM, Chhabra A. Pudendal nerve and branch neuropathy: Magnetic resonance neurography evaluation. *Acta Radiol*. 2017;58(6):726-733. doi:10.1177/0284185116668213.**  
~~Wadhwa V, Hamid AS, et al. Pudendal nerve and branch neuropathy: Magnetic resonance neurography evaluation. *Acta Radiol*. Epub 2016.~~

Wald A, Bharucha AE, et al. ACG Clinical Guideline: Management of Benign Anorectal Disorders. *Am J Gastroenterol*. 2014.

Wallis CJD, Haider MA, Nam RK, et al. Role of mpMRI of the prostate in screening for prostate cancer. *Transl Androl Urol*. 2017 Jun; 6(3):464-471.

**van der Leest M, Cornel E, Israël B, et al. Head-to-head comparison of transrectal ultrasound-guided prostate biopsy versus multiparametric prostate resonance imaging with subsequent magnetic resonance-guided biopsy in biopsy-naïve men with elevated prostate-specific antigen: A large prospective multicenter clinical study. *Eur Urol*. 2019;75(4):570-578. doi:10.1016/j.eururo.2018.11.023.**

Villavicencio CP, Adam SZ, Nikolaidis P, et al. Imaging of the urachus: Anomalies, complications and mimics. *Radiographics*. 2016; 36(7).

Vogel JD, Johnson EK, et al. Clinical Practice Guideline for Management of Anorectal Abscess, Fistula-in-ano, and Rectovaginal Fistula. *Dis Colon Rect*. 2016; 59:1117-1133.

Yanny S, Cahir JG, Barker T, et al. MRI of aseptic lymphocytic vasculitis-associated lesions in metal-on-metal hip replacements. *AJR Am J Roentgenol*. 2012; 198:1394-1402. doi: 10.2214/AJR.11.7504.

**Reviewed / Approved by**

Reviewed / Approved by

*M. Atif Khalid MD*

**MD**

M. Atif Khalid, M.D., Medical Director, Radiology



### GENERAL INFORMATION

It is an expectation that all patients receive care/services from a licensed clinician. All appropriate supporting documentation, including recent pertinent office visit notes, laboratory data, and results of any special testing must be provided. If applicable: All prior relevant imaging results and the reason that alternative imaging cannot be performed must be included in the documentation submitted.

**Disclaimer:** Magellan Healthcare service authorization policies do not constitute medical advice and are not intended to govern or otherwise influence the practice of medicine. These policies are not meant to supplant your normal procedures, evaluation, diagnosis, treatment and/or care plans for your patients. Your professional judgement must be exercised and followed in all respects with regard to the treatment and care of your patients. These policies apply to all Magellan Healthcare subsidiaries including, but not limited to, National Imaging Associates (“Magellan”). The policies constitute only the reimbursement and coverage guidelines of Magellan. Coverage for services varies for individual members in accordance with the terms and conditions of applicable Certificates of Coverage, Summary Plan Descriptions, or contracts with governing regulatory agencies. Magellan reserves the right to review and